COHERUS BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
COHERUS BIOSCIENCES INC. - More news...
COHERUS BIOSCIENCES INC. - More news...
- Thinking about buying stock in YanGuFang International, Broadcom, Applied Digital, Intelligent Bio Solutions, or Coherus Biosciences?
- Thinking about buying stock in Riot Platforms, Coherus Biosciences, AC Immune, Wisekey International Holding, or NXU Inc.?
- Thinking about buying stock in Applied Therapeutics, Coherus Biosciences, Tempest Therapeutics, Bluegreen Vacations Holding, or Adams Resources & Energy?
- Thinking about buying stock in Coherus Biosciences, Vyne Therapeutics, Intuitive Machines, SoFi Technologies, or Cybin?
- Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
- Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
- Thinking about buying stock in Coherus Biosciences, Macy's, Salarius Pharmaceuticals, Verb Technology, or Senseonics?
- Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada
- Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada
- Investor Network: Coherus BioSciences, Inc. to Host Earnings Call
- Covered Call reports for Amazon.com, Coherus Biosciences, 3D Systems, The Kroger Co and Tesla Motors include trade ideas that offer returns of 24% or more!
- Investor Network: Coherus BioSciences, Inc. to Host Earnings Call
-
Coherus BioSciences
- Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619
- Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
- Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
- Coherus BioSciences to Present at BMO – Prescriptions for Success Healthcare Conference on December 14th
- Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results
- Coherus BioSciences Receives Decision Denying Institution of the ‘166 IPR Related to AbbVie’s HUMIRA® Formulation
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th
- Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in November
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
- Coherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214
